

CONCLUSIONS

From the present study we can conclude the following:

1. CD81 expression was significantly lower on leukemic blast cells of precursor B-ALL cases than on hematogones, thus it could be a useful marker to differentiate between them.
2. CD81 expression was significantly lower in common and pre-B-ALL subtypes than in pro-B-ALL subtype, which may increase its value in differentiating between CD10+ve blasts and hematogones.
3. A cutoff value of 1134 for CD81 MFI was established to differentiate between leukemic blast cells and hematogones, where leukemic blasts were ≤ 1134 and hematogones were >1134 .
4. Diminished CD81 expression is a sensitive marker for residual B-ALL. Thus, it could be a useful addition to flow cytometric panels used for assessment of minimal residual disease.
5. CD81 expression on blast cells of precursor B-ALL was stable with time and following chemotherapy, which adds to its usefulness in minimal residual disease detection.
6. No significant correlation was found between CD81 MFI and different studied hematological parameters.